-
1.发明公开
公开(公告)号：EP3484864A1
公开(公告)日：2019-05-22
申请号：EP17743287.9
申请日：2017-07-13
申请人： Centre National de la Recherche Scientifique - CNRS , INSERM (Institut National de la Santé et de la Recherche Médicale) , Université de Strasbourg , Universite Paris-Sud , Centre International de Recherche aux Frontières de la Chimie
发明人： BONNET, Dominique , FROSSARD, Nelly , GALZI, Jean-Luc , GUIGNABERT, Christophe , HIBERT, Marcel , SIMONIN, Frédéric , MULLER, Sylviane
IPC分类号： C07D401/04 , C07D403/04 , C07D403/10 , C07D405/04 , C07D239/36 , C07D409/04 , C07D413/04 , C07D413/10 , C07D417/04 , A61K31/513 , A61P35/00
-
公开(公告)号：EP2717875A2
公开(公告)日：2014-04-16
申请号：EP12731173.6
申请日：2012-06-06
发明人： FEVE, Marie , ZENIOU-MEYER, Maria , HAIECH, Jacques , CHNEIWEISS, Hervé , KILHOFFER, Marie-Claude , MAMERI, Samir , HIBERT, Marcel
IPC分类号： A61K31/4402 , A61K31/4425 , A61P35/00 , A61K31/05 , A61K31/44 , A61K31/4406 , A61K31/4409
CPC分类号： C07D213/16 , A61K31/05 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4425 , C07D213/26 , C07D213/30 , C07D213/34 , C07F7/1804 , G01N33/5011
摘要： The present invention provides compounds having the formula A: (A) or pharmaceutically acceptable salt thereof, wherein W, R1, R2 and R5 are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as cytotoxic agents towards proliferating and/or quiescent cancer stem cells, and thus are useful, for example, for the treatment of cancer.
-
公开(公告)号：EP4378526A1
公开(公告)日：2024-06-05
申请号：EP22306768.7
申请日：2022-11-30
发明人： HIBERT, Marcel
IPC分类号： A61P25/00 , C07D487/04 , A61K31/5517
CPC分类号： C07D487/04 , A61P25/00
摘要： The present invention concerns a non peptidergic agonist of oxytocin receptor of formula (I), a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable vehicle, and notably said compound for the treatment of all known pathologies where oxytocin has a beneficial effect such as autism spectrum disorders, in particular for the treatment of social interaction impairments in autism spectrum disorders.
-
4.发明授权PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS 有权PYRIDAZINVERBINDUNGEN，ZUSAMMENSETZUNGEN UND VERFAHREN
公开(公告)号：EP1812408B1
公开(公告)日：2013-10-09
申请号：EP05817588.6
申请日：2005-11-02
申请人： Northwestern University , Université de Strasbourg , Centre National de la Recherche Scientifique
发明人： WATTERSON, D. Martin , VAN ELDIK, Linda , HAIECH, Jacques , HIBERT, Marcel , BOURGUIGNON, Jean-jacques , VELENTZA, Anastasia , HU, Wenhui , ZASADZKI, Magdelena
IPC分类号： A61K31/50 , C07D403/12 , A61K31/502 , C07D401/04 , A61P25/28 , A61P37/00
CPC分类号： C07D401/12 , A61K31/502 , C07D237/20 , C07D237/24 , C07D237/34 , C07D401/04 , C07D403/12 , C07D413/12 , C07D413/14 , C07D487/04 , C07H19/16
摘要： The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of making and using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications. Compounds of Formula Ia or Ib or wherein R is a substituted amino group, R 2 is an unsaturated 5 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, R 3 , R 4 , R 5 , and R 6 are hydrogen, and R 7 is absent; or a pharmaceutically acceptable salt thereof.
摘要翻译： 本发明涉及新颖的化合物，组合物和制备和使用它们的方法。 特别地，本发明提供哒嗪化合物和/或相关杂环衍生物，包含其的组合物，以及制备和使用哒嗪化合物和/或相关杂环衍生物的方法及其组合物，用于调节细胞途径（例如，信号转导 途径），用于治疗或预防炎性疾病（如阿尔茨海默病），用于研究，药物筛选和治疗应用。 式Ia或Ib的化合物或其中R是取代的氨基，R 2是含有1至4个氮原子的不饱和5至6元杂单环基团，R 3，R 4，R 5和R 6是氢，和 R 7不存在 或其药学上可接受的盐。
-
公开(公告)号：EP4378525A1
公开(公告)日：2024-06-05
申请号：EP22306767.9
申请日：2022-11-30
发明人： HIBERT, Marcel
IPC分类号： A61P25/00 , C07D487/04 , A61K31/5517
CPC分类号： C07D487/04 , A61P25/00
摘要： The present invention concerns a non peptidergic agonist of oxytocin receptor of formula (I), a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable vehicle, and notably said compound for the treatment of all known pathologies where oxytocin has a beneficial effect such as autism spectrum disorders, in particular for the treatment of social interaction impairments in autism spectrum disorders.
-
-
-
-
搜索结果
5 条记录 (耗时 0.025 秒)
